GH
ADCT icon

Grosvenor Holdings’s ADC Therapeutics ADCT Stock Holding History

Grosvenor Holdings’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$22.3M Hold
1,517,212
– – 4.35% 9
2021
Q4 		$30.6M Hold
1,517,212
– – 3.17% 12
2021
Q3 		$41.2M Hold
1,517,212
– – 5.05% 9
2021
Q2 		$36.9M Hold
1,517,212
– – 3.67% 12
2021
Q1 		$37M Hold
1,517,212
– – 2.72% 17
2020
Q4 		$48.6M Hold
1,517,212
– – 2.65% 19
2020
Q3 		$50.1M Buy
1,517,212
+240,000
+19% +$10.4M 3.69% 13
2020
Q2 		$59.8M Buy
+1,277,212
New +$48.5M 5.57% 10

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Grosvenor Holdings's ADCT Position: Q1 2022 in Review

Grosvenor Holdings held its ADC Therapeutics (ADCT) position steady in Q1 2022 at 1,517,212 shares worth $22.3M. The position accounts for 4.35% of the portfolio, ranked #9.

Grosvenor Holdings first reported a position in ADCT in Q2 2020 and has held it in 8 quarters since. The position peaked at $59.8M in Q2 2020. 49 funds tracked by Wall St. Rank hold ADCT as of Q1 2022.

  • Grosvenor Holdings held 1,517,212 shares of ADC Therapeutics worth $22.3M as of Q1 2022.
  • Grosvenor Holdings left its ADC Therapeutics share count unchanged in Q1 2022.
  • ADC Therapeutics made up 4.35% of Grosvenor Holdings's portfolio in Q1 2022, its #9 holding.
  • Grosvenor Holdings first reported a position in ADC Therapeutics in Q2 2020 and has held it in 8 quarters since.
  • Grosvenor Holdings's ADC Therapeutics position peaked at $59.8M in Q2 2020.
  • 49 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2022.

Based on Grosvenor Holdings's 13F filing for Q1 2022, filed 16 May 2022.